Observational studyJournal of pediatric gastroenterology and nutrition2026
Recovery from symptoms using an extensively hydrolyzed formula with synbiotic in infants with presumed cow's milk allergy.
Observational study in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04893330 (Interest of Peticate Syneo Infant Formula in Children Allergic to Cow's Milk Protein), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interest of Peticate Syneo Infant Formula in Children Allergic to Cow's Milk Protein: Real Life Study
Who cites it
1 citing paper in PubMed.
- Recovery from symptoms using an extensively hydrolyzed formula with synbiotic in infants with presumed cow's milk allergy.Journal of pediatric gastroenterology and nutrition · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveExtensively hydrolyzed formulas (eHF) are the first-line approach for cow's milk protein allergy (CMPA). This study evaluated the effects of eHF with synbiotic eHF (SeHF) on the general condition and symptoms of presumed CMPA infants during the initial 4-week exclusion diet period.
methodsThis observational prospective study (NCT04893330) recruited 114 patients (intention-to-treat [ITT] population; aged ≤8 months) with presumed CMPA. Patients were followed up for 28 days (D28) (per-protocol [PP], n = 80). Changes in general condition and presumed allergic symptoms were assessed using a 4-level Likert scale. Secondary endpoints included the time to symptom improvement, formula acceptability and consumption, and the parent's quality of life (QoL).
resultsThe presumed allergic symptoms had improved/resolved for 86.3% of the PP population in 7-10 days on average. 86.8% of ITT cases had digestive symptoms at baseline and those reduced/disappeared in 93.2% of the PP cases at D28. The majority of parents agreed that the formula was suitable for the baby (78.8%). The QoL significantly improved from 60 ± 28 to 42 ± 24 (p < 0.001).
conclusionThis study reflects the real-world management of presumed CMPA in our private practices using SeHF, which effectively improved CMPA symptoms. It also highlights the importance of waiting at least 2 weeks before reconsidering CMPA diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.